MIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced selection of a novel modified release oral formulation for enobosarm, a selective androgen receptor modulator, for chronic weight loss management, following confirmation of pharmacokinetic endpoints in a clinical study.
Related Questions
What implications does this have for Veruâs overall pipeline prioritization and allocation of R&D resources?
How will the selection of a novel modifiedârelease enobosarm formulation affect Veruâs revenue forecasts and earnings guidance?
What is the estimated market potential for chronic weightâloss management with enobosarm compared to existing therapies?
When will detailed pharmacokinetic study results be released and how might they influence the timeline for FDA approval?
Does this development shorten the expected time to market or alter the regulatory pathway for enobosarm?
How does the efficacy and safety profile of the modifiedârelease formulation compare to competitorsâ selective androgen receptor modulators?
What are the potential partnership, licensing, or coâmarketing opportunities arising from this new formulation?
Will this news impact Veruâs valuation multiples relative to other cardiometabolic biotech peers?
How might the announcement affect Veruâs cash burn rate and the need for additional financing or equity raises?
Are there any upcoming FDA meetings, advisory committee reviews, or regulatory milestones tied to this formulation?